51555-87-4

中文名称 D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷

英文名称 THIODIGALACTOSIDE

CAS 51555-87-4

分子式 C12H22O10S

分子量 358.36

MOL 文件 51555-87-4.mol

更新日期 2025/04/17 10:05:56

51555-87-4 结构式

基本信息物理化学性质安全数据 D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷价格(试剂级) 常见问题列表

基本信息

中文别名

硫代半乳糖苷
N4苯甲酰基5'-O-DMT-5-甲基
D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷
(D-GALACTOPYRANOSYL)-B-D-THIOGALACTOPYRANOSIDE 硫代二半乳糖苷

英文别名

TDG
THIODIGALACTOSIDE
Galactosyl 1-thiogalactoside
D-Galactopyranosyl-b-D-thiogalactopyranoside
d-galactopyranosyl-β-d-thiogalactopyranoside
D-GALACTOPYRANOSYL BETA-D-THIOGALACTOPYRANOSIDE
D-Galactopyranosyl-β-D-thiogalactopyranoside ,98%
β-D-Galactopyranoside, β-D-galactopyranosyl 1-thio-

所属类别

生物化工：抑制剂

物理化学性质

熔点>225°C (dec.)

储存条件−20°C

溶解度二甲基亚砜（微溶）

形态固体

颜色白色

水溶解性H2O: 2mg/mL, clear

InChIInChI=1/C12H22O10S/c13-1-3-5(15)7(17)9(19)11(21-3)23-12-10(20)8(18)6(16)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11+,12?/s3

InChIKeySYKYBMOFPMXDRQ-YSLNCGCNNA-N

SMILESC1([C@H](O)[C@H]([C@@H](O)[C@@H](CO)O1)O)S[C@H]1[C@H](O)[C@H]([C@@H](O)[C@@H](CO)O1)O |&1:1,3,4,6,12,13,15,16,18,r|

安全数据

WGK Germany3

海关编码29389090

D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/05/22	HY-130208	D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷 Thiodigalactoside	51555-87-4	5 mg	253元
2025/05/22	HY-130208	D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷 Thiodigalactoside	51555-87-4	10 mg	380元
2025/05/22	HY-130208	D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷 Thiodigalactoside	51555-87-4	25mg	560元

常见问题列表

生物活性

Thiodigalactoside (TDG) 是一种具有口服活性的，有效的半乳凝素 (GAL) 抑制剂，对于 GAL-1 和 GAL-3 的 Kd 值分别为 24 μM，49 μM。Thiodigalactoside 是一种不可代谢的二糖，具有抗炎和抗癌活性。Thiodigalactoside 可显着降低饮食诱发的肥胖大鼠的体重增加。

靶点

Kd: 24 μM (GAL1) and 49 μM (GAL3)

体外研究

Thiodigalactoside (TDG; 250 and 500 μM) exhibits dose-dependent reduction of fat accumulation based on triglyceride (TG) content and Oil Red O (ORO) staining.

体内研究

Thiodigalactoside (TDG; 5 mg/kg; IP; once per week for 5 weeks) results in dramatic inhibition of HFD-induced body weight gain.
Thiodigalactoside (5 mg/kg; oral; daily or weekly for 5 weeks) gave less reduction in body weight gain compare with i.p..

Animal Model:	Five-week-old Sprague-Dawley (SD) male rats
Dosage:	5 mg/kg
Administration:	IP; once per week for 5 weeks
Result:	Resulted in dramatic inhibition of HFD-induced body weight gain by inhibiting adipogenesis and lipogensis as well as by increasing expression of the proteins associated with thermogenesis and energy expenditure.